Female Contraception – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Female Contraception – Pipeline Review, H1 2020’, provides an overview of the Female Contraception pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Female Contraception

– The report reviews pipeline therapeutics for Female Contraception by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Female Contraception therapeutics and enlists all their major and minor projects

– The report assesses Female Contraception therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Female Contraception

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Female Contraception

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Female Contraception pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adare Pharmaceuticals Inc

Agile Therapeutics Inc

Dare Bioscience Inc

Evestra Inc

Exeltis Pharmaceuticals Holding SL

Hervana Ltd

Luye Pharma Group Ltd

MedinCell SA

Micron Biomedical Inc

Mithra Pharmaceuticals SA

Mucommune LLC

Navad Life Sciences Pte Ltd

Orion Biotechnology Canada Ltd

Ovastasis LLC

Teva Pharmaceutical Industries Ltd

Viramal Ltd

Yaso Therapeutics Inc

YourChoice Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Female Contraception - Overview

Female Contraception - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Female Contraception - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Female Contraception - Companies Involved in Therapeutics Development

Adare Pharmaceuticals Inc

Agile Therapeutics Inc

Dare Bioscience Inc

Evestra Inc

Exeltis Pharmaceuticals Holding SL

Hervana Ltd

Luye Pharma Group Ltd

MedinCell SA

Micron Biomedical Inc

Mithra Pharmaceuticals SA

Mucommune LLC

Navad Life Sciences Pte Ltd

Orion Biotechnology Canada Ltd

Ovastasis LLC

Teva Pharmaceutical Industries Ltd

Viramal Ltd

Yaso Therapeutics Inc

YourChoice Therapeutics Inc

Female Contraception - Drug Profiles

(dienogest + ethinylestradiol) PR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(drospirenone + estetrol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(estradiol + segesterone acetate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(ethinylestradiol + gestodene) ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-200 ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-200 SP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Contraception - Dormant Projects

Female Contraception - Discontinued Products

Female Contraception - Product Development Milestones

Featured News & Press Releases

May 20, 2020: Mithra and Searchlight Pharma announce filing of New Drug Submission for Estelle in Canada

Apr 22, 2020: MedinCell launches regulatory development of mdc-WWM program

Apr 16, 2020: Mayne Pharma submits New Drug Application for E4/DRSP to the FDA

Mar 03, 2020: Mithra receives acceptance of marketing authorization application (MAA) to market Estelle in Belgium and Luxembourg

Feb 27, 2020: EMA accepts Richter’s Marketing Authorization Application for Estelle, a novel combined oral contraceptive

Feb 10, 2020: Mithra’s E4-based product Estelle to benefit from positive ruling on Patent Income Deduction

Dec 05, 2019: Once-A-month oral contraceptive pill in development

Nov 28, 2019: Medincell receives $19 million grant for Its mdc-WWM program

Oct 22, 2019: Mithra announces publication of Estelle abstracts in connection with the 13th Annual Meeting of the European Society of Gynecology

Oct 16, 2019: Presentation of Estelle phase III results at the 13th Meeting of the European Society of Gynecology

Aug 08, 2019: Mithra obtains crucial additional Estelle patent in Japan

Jul 23, 2019: Jubilant Cadista Pharmaceuticals issues voluntary nationwide recall of Drospirenone and Ethinyl Estradiol Tablets, USP, due to out-of-specification dissolution test results

Apr 02, 2019: Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle

Feb 13, 2019: Mithra successfully produces its first commercial batch of Myring for Europe

Jan 30, 2019: Mithra announces positive top-line results of Estelle phase III oral contraceptive study in U.S/Canada

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Female Contraception, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Female Contraception – Pipeline by Adare Pharmaceuticals Inc, H1 2020

Female Contraception – Pipeline by Agile Therapeutics Inc, H1 2020

Female Contraception – Pipeline by Dare Bioscience Inc, H1 2020

Female Contraception – Pipeline by Evestra Inc, H1 2020

Female Contraception – Pipeline by Exeltis Pharmaceuticals Holding SL, H1 2020

Female Contraception – Pipeline by Hervana Ltd, H1 2020

Female Contraception – Pipeline by Luye Pharma Group Ltd, H1 2020

Female Contraception – Pipeline by MedinCell SA, H1 2020

Female Contraception – Pipeline by Micron Biomedical Inc, H1 2020

Female Contraception – Pipeline by Mithra Pharmaceuticals SA, H1 2020

Female Contraception – Pipeline by Mucommune LLC, H1 2020

Female Contraception – Pipeline by Navad Life Sciences Pte Ltd, H1 2020

Female Contraception – Pipeline by Orion Biotechnology Canada Ltd, H1 2020

Female Contraception – Pipeline by Ovastasis LLC, H1 2020

Female Contraception – Pipeline by Teva Pharmaceutical Industries Ltd, H1 2020

Female Contraception – Pipeline by Viramal Ltd, H1 2020

Female Contraception – Pipeline by Yaso Therapeutics Inc, H1 2020

Female Contraception – Pipeline by YourChoice Therapeutics Inc, H1 2020

Female Contraception – Dormant Projects, H1 2020

Female Contraception – Dormant Projects, H1 2020 (Contd..1), H1 2020

Female Contraception – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Female Contraception, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports